Recent advances in glioblastoma multiforme therapy: A focus on autophagy regulation

Despite conventional treatment options including chemoradiation, patients with the most aggressive primary brain tumor, glioblastoma multiforme (GBM), experience an average survival time of less than 15 months. Regarding the malignant nature of GBM, extensive research and discovery of novel treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicine & pharmacotherapy 2022-11, Vol.155, p.113740-113740, Article 113740
Main Authors: Sanati, Mehdi, Binabaj, Maryam Moradi, Ahmadi, Seyed Sajad, Aminyavari, Samaneh, Javid, Hossein, Mollazadeh, Hamid, Bibak, Bahram, Mohtashami, Elmira, Jamialahmadi, Tannaz, Afshari, Amir R., Sahebkar, Amirhossein
Format: Article
Language:English
Subjects:
Autophagy
Glioblastoma
Therapy
Tumorigenesis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite conventional treatment options including chemoradiation, patients with the most aggressive primary brain tumor, glioblastoma multiforme (GBM), experience an average survival time of less than 15 months. Regarding the malignant nature of GBM, extensive research and discovery of novel treatments are urgently required to improve the patients’ prognosis. Autophagy, a crucial physiological pathway for the degradation and recycling of cell components, is one of the exciting targets of GBM studies. Interventions aimed at autophagy activation or inhibition have been explored as potential GBM therapeutics. This review, which delves into therapeutic techniques to block or activate autophagy in preclinical and clinical research, aims to expand our understanding of available therapies battling GBM. [Display omitted] •Glioblastoma multiforme (GBM) is among the most difficult-to-treat types of cancer.•Autophagy is an emerging therapeutic target in GBM.•This review delves into the role of autophagy modulation in GBM treatment.
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2022.113740